A phase I trial of GRN163L (GRN), a first-in-class telomerase inhibitor, in advanced solid tumors

被引：0
|
作者：
Ratain, M. J.
Benedetti, F. M.
Janisch, L.
Khor, S.
Schilsky, R. L.
Cohen, E. E.
Maitland, M. L.
Elias, L.
LoRusso, P. M.
机构：
[1] Univ Chicago, Chicago, IL 60637 USA
[2] Geron Corp, Menlo Pk, CA USA
[3] Wayne State Univ, Detroit, MI USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3581
引用
收藏
页数：1
相关论文
共 50 条
  • [31] The telomerase template antagonist GRN163L in combination with chemotherapeutics reduces tumor volume in multiple myeloma xenograft models.
    Ertem, SA
    Wu, KD
    Ponomarev, V
    Chin, AC
    Moore, MAS
    BLOOD, 2005, 106 (11) : 971A - 971A
  • [32] Telomerase inhibition, telomere shortening and apoptotic cell death in multiple myeloma cells following exposure to a novel and potent telomerase inhibitor (GRN163L), targeting RNA component of telomerase.
    Nimmanapalli, R
    Gerbino, E
    Dalton, WS
    Alsina, M
    BLOOD, 2004, 104 (11) : 184A - 184A
  • [33] Activity of the Telomerase Inhibitor GRN163L (Imetelstat) on Acute Myeloblastic Leukemia Blasts Is Enhanced By DNA Methyltransferase Inhibitors Irrespective of TERT Promoter Methylation Status
    Cantilena, Caroline R.
    Zhao, Xin
    Kajigaya, Sachiko
    Dunavin, Neil
    Tian, Xin
    Strickland, Stephen A.
    Savani, Bipin N.
    Mohan, Sanjay R.
    Rezvani, Katayoun
    Feng, Xingmin
    Townsley, Danielle M.
    Battiwalla, Minoo
    Ito, Sawa
    Barrett, Austin John
    BLOOD, 2015, 126 (23)
  • [34] First-In-Human, First-In-Class, Phase I Trial of the Fucosylation Inhibitor SGN-2FF in Patients with Advanced Solid Tumors
    Do, Khanh T.
    Chow, Laura Quan Man
    Reckamp, Karen
    Sanborn, Rachel E.
    Burris, Howard
    Robert, Francisco
    Camidge, D. Ross
    Steuer, Conor E.
    Strickler, John H.
    Weise, Amy
    Specht, Jennifer M.
    Gutierrez, Martin
    Haughney, Peter
    Hengel, Shawna
    Derleth, Christina Louise
    Yap, Timothy A.
    ONCOLOGIST, 2021, 26 (11): : 925 - +
  • [35] Anti-cell adhesive effects of a novel telomerase inhibitor GRN 163L in cancer cells
    Jackson, Shalmica R.
    Zhu, Chun-Hong
    Watkins, Linda
    Gryaznov, Sergei M.
    Paulson, Vera
    Wright, Woodring E.
    Shay, Jerry W.
    CANCER RESEARCH, 2006, 66 (08)
  • [36] Phase I Trial of TTI-101, a First-in-Class Oral Inhibitor of STAT3, in Patients with Advanced Solid Tumors
    Tsimberidou, Apostolia M.
    Vining, David J.
    Arora, Sukeshi P.
    de Achaval, Sofia
    Larson, Jeffrey
    Kauh, John
    Cartwright, Carrie
    Avritscher, Rony
    Alibhai, Imran
    Tweardy, David J.
    Kaseb, Ahmed O.
    CLINICAL CANCER RESEARCH, 2025, 31 (06) : 965 - 974
  • [37] Antiadhesive effects of GRN163L -: An oligonucleotide N3′→P5′ thio-phosphoramidate targeting telomerase
    Jackson, Shalmica R.
    Zhu, Chun-Hong
    Paulson, Vera
    Watkins, Linda
    Dikmen, Z. Gunnur
    Gryaznov, Sergei M.
    Wright, Woodring L.
    Shay, Jerry W.
    CANCER RESEARCH, 2007, 67 (03) : 1121 - 1129
  • [38] Phase I trial in advanced refractory solid tumors of the new drug first-in-class PDM08.
    Barriuso, Jorge
    Moreno, Victor
    Coronado, Monica
    Galicia, Ignacio
    Soria, Irene
    de Castro, Javier
    Belda-Iniesta, Cristobal
    Martinez Marin, Virginia
    Custodio, Ana
    Redondo, Andres
    Lamarca, Angela
    Hindi, Nadia
    Luis Subiza, Jose
    Frias, Jesus
    Feliu, Jaime
    Carcas, Antonio
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [39] Single agent and combination treatment studies with the telomerase inhibitor GRN163L in ovarian cancer and non-small cell lung carcinoma (NSCLC) xenograft models
    Go, N.
    Li, Y.
    Tressler, R.
    EJC SUPPLEMENTS, 2006, 4 (12): : 189 - 189
  • [40] Extremely short telomeres and high telomerase activity in T-cell prolymphocytic leukemia (T-PLL): An optimal target for telomerase inhibition with GRN163L?
    Roeth, A.
    de Beer, D.
    Duerig, J.
    Duehrsen, U.
    Elias, L.
    Tressler, R.
    Baerlocher, G. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345